The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
Abstract
Purpose: This phase III study compared the time to progression (TTP) of an oral regimen of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine composed of a fixed combination of tegafur and uracil in a 1:4 molar ratio (UFT) and leucovorin (LV) to intravenous (IV) fluorouracil (5-FU) and LV in previously untreated metastatic colorectal carcinoma (CRC) patients. Secondary end points were survival, tumor response, safety, and quality of life. Patients and Methods: Between May 1996 and July 1997, 380 patients were randomized to receive either UFT (300 mg/m 2/d) and LV (90 mg/d), administered for 28 days every 35 days, or 5-FU (425 mg/m 2/d) and LV (20 mg/m 2/d), given IV for 5 days every 35 days. Results: No statistically significant difference in TTP was observed between treatments. With 320 events assessed, the median TTP was 3.4 months (95% Confidence interval [CI], 2.6 to 3.8) on UFT/LV and 3.3 months (95% CI, 2.5 to 3.7) on 5-FU/LV (P = .591, stratified log-rank test). There were no statistically significant differences in survival, tumor response, duration of response, and time to response. Substantial safety benefits were observed in patients treated with UFT/LV. They experienced significantly less stomatitis/mucositis (P < .001) and myelosuppression, resulting in fewer episodes of febrile neutropenia (P < .001) and less documented infection (P = .04). Concomitant medication usage was significantly greater on 5-FU/LV (P = .010). With respect to quality of life, after correcting for baseline imbalances, there were no significant differences between treatments for any scale, except diarrhea. Conclusion: The oral UFT/LV regimen failed to achieve improved TTP; however, the study confirms significant safety improvements compared with bolus IV 5-FU/LV for the first-line treatment of metastatic CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationLandis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654
Erlichman, C., Fine, S., Wong, A., & Elhakim, T. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.3.469 · Cited by 503
Cancer in the European community and its member states
Møller Jensen, O., Estève, J., Møller, H., & Renard, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90278-2 · Cited by 455
Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., & Mangalik, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1303 · Cited by 359
Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323
Pazdur, R., Lassere, Y., Rhodes, V, Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Markowitz, A. B., Abbruzzese, J. L., & Bready, B. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.11.2296 · Cited by 205
Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal Cancer
(2001) · New England Journal of Medicine · doi:10.1056/nejm200107123450213 · Cited by 191
Combining Dependent Tests with Incomplete Repeated Measurements
Wei, L. J., & Johnson, W. E. (1985) · Biometrika · doi:10.2307/2336088 · Cited by 188
Report on nationwide pooled data and cohort investigation in UFT phase II study
Ota, K., Taguchi, T., & Kimura, K. (1988) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254241 · Cited by 179
Combining dependent tests with incomplete repeated measurements
WEI, L. J., & JOHNSON, W. E. (1985) · Biometrika · doi:10.1093/biomet/72.2.359 · Cited by 177
Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer
Glimelius, B. L. G., Hoffman, K., Graf, W. D., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059157 · Cited by 151
Capecitabine as first-line treatment in colorectal cancer
Twelves, C. J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00415-4 · Cited by 139
Saltz, L. B., Leichman, C. G., Young, C. W., Muggia, F. M., Conti, J. A., Spiess, T., Jeffers, S., & Leichman, L. P. (1995) · Cancer · Cited by 95
González‐Barón, M., Feliú, J., de la Gándara, I., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00487-4 · Cited by 82
Labianca, R., Pancera, G., Aitini, E., et al. (1991) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058047 · Cited by 74
Uracil and tegafur modulated with leucovorin
Feliú, J., Bar�n, M. G., Espinosa, E., Gir�n, C. G., la G�ndara, I. D., Espinosa, J., Colmenarejo, A., Jal�n, J. I., Fern�ndez, Y., de Castro, J., et al. (1997) · Cancer · Cited by 69
Meropol, N. J., Rustum, Y. M., Petrelli, N. J., et al. (1996) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050432 · Cited by 62
Phase II trial of UFT in advanced colorectal and gastric cancer
Malik, S., Talbot, D. C., Clarke, P., et al. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.431 · Cited by 60
MacKay, H. J., Hill, M. E., Twelves, C. J., Glasspool, R. M., Price, T. J., Campbell, S., Massey, A., Macham, M. A., Uzzel, M., Bailey, S., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg340 · Cited by 41
Self-citationPhase I trial of Uracil-Tegafur (UFT) plus oral leucovorin: 14-day schedule
Pazdur, R. M., Lassere, Y., Diaz-Canton, E. A., et al. (1997) · Investigational New Drugs · doi:10.1023/a:1005808822565 · Cited by 38
Tirapazamine-cisplatin: the synergy
Gatzemeier, U., Rodriguez, G., Treat, J., Miller, V., von Roemeling, R., Viallet, J., & Rey, A. A. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.431 · Cited by 34
Tegafur-Uracil (UFT) Plus Folinic Acid in Advanced Rectal Cancer
Sanchíz, F., & Milla, A. (1994) · Japanese Journal of Clinical Oncology · doi:10.1093/oxfordjournals.jjco.a039730 · Cited by 32
Cao, S., Frank, C., Shirasaka, T., & Rustum, Y. M. (1995) · PubMed · Cited by 28
Rustum, Y. M. (2009) · Oncology · doi:10.1159/000227738 · Cited by 24
Abad, A., Navarro, M., Sastre, J., et al. (1997) · PubMed · Cited by 22
Bobbio-Pallavicini, E., Porta, C., Moroni, M., Spaghi, A., Casagranda, I., & Nastasi, G. (1993) · Journal of Chemotherapy · doi:10.1080/1120009x.1993.11739210 · Cited by 22
Cited by
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Watanabe, T., Itabashi, M., Shimada, Y., Tanaka, S., Ito, Y., Ajioka, Y., Hamaguchi, T., Hyodo, I., Igarashi, M., Ishida, H., et al. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0801-z · Cited by 590
Metadata
- Authors
- Carmichael, J., Popiela, T., Radstone, D., Falk, S., Borner, M., Oza, A., Skovsgaard, T., Munier, S., & Martin, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-09-01
- Volume
- 20
- Issue
- 17
- Pages
- 3617-3627
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2032541464
- Cited by
- 268
- References
- 39
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.